Cutler Group LP Viridian Therapeutics, Inc.\De Call Options Transaction History

Cutler Group LP

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 04, 2022	BUY	$9.55 - $19.0 $111,735 - $222,300	11,700 Added 229.41%	16,800 $29,000
Q1 2022 Apr 14, 2022	BUY	$16.79 - $20.88 $43,654 - $54,288	2,600 Added 104.0%	5,100 $21,000
Q3 2021 Oct 26, 2021	BUY	$10.69 - $18.2 $26,725 - $45,500	2,500 New	2,500 $10,000

182

76.9M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $795M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Cutler Group LP, based on Form 13F filings with the SEC.

Stay updated on Cutler Group LP with notifications on news.